Overview
PreventionGenetics acquired by Exact Sciences to enable earlier cancer detection and hereditary cancer testing.
Significance
During the past two decades since publication of the first draft of the human genome project, the use of genotyping and genomic testing has become integral to many cancer treatments, enabling more personalized or precision therapies. Today, precision medicine has grown into one of the highest growth market segments of the healthcare industry, valued at ~$60 billion and projected to grow to ~$100 billion over the next five years. As the market for precision medicine has grown, so, too has the need for genomic and genetic testing to support development of these drugs.
With a goal to improve lives through genetic testing, PreventionGenetics offers more than 5,000 predefined genetic tests for nearly all clinically relevant genes, additional custom panels, and comprehensive germline whole exome and whole genome sequencing tests. The company’s portfolio of tests for proactive health and wellness, cancer risk and screening, pediatric and adult-onset rare diseases, and others made PreventionGenetics the perfect complement to Exact Sciences’ advanced cancer diagnostics portfolio and supports its entrance into hereditary cancer testing (HCT).
Crosstree’s Role
Crosstree acted as exclusive financial advisor to PreventionGenetics in its acquisition by Exact Sciences through:
- Synthesizing PreventionGenetics’ highly-specialized capabilities into a cohesive value proposition
- Evaluating a broad slate of potential strategic partners to ensure continued growth
- Leveraging market expertise to identify the ideal partner to maximize synergies and optimize cultural fit
Latest Deals
Myonex Acquired Creapharm's Clinical & Commercial Packaging and Bioservices Business Units to Expand Clinical Trial Supply Services and Gain of Foothold in Europe
.png)
Myonex Acquired SaveWay Compounding Pharmacy to Expand and Bolster its Clinical Trial Services Across the US
%20(1).png)
physIQ Acquired by Prolaio to Enhance its Next-Gen Connected Heart Care Technology for Clinical Care and Research
.png)
Continuum Clinical, a BC Worldwide company, Acquired by Spectrum Science, a Portfolio Company of Knox Lane, to Bolster Patient Engagement Capabilities
%20(NEW).png)
Yecuris Corporation Acquired by Janvier Group to Expand Preclinical Service Offering Internationally
.png)
Modular Devices, a Portfolio Company of O2 Investment Partners, Partners with Flow Clean Rooms and Supply to Bolster Existing Clean Room Manufacturing Capabilities and Expand Overall Offering
Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities
Versiti Acquired Pearl Pathways to Expand Clinical Trial Services Capabilities
VaxTRIALS Acquired by Emmes, a portfolio company of New Mountain Capital, to Expand Vaccine and Clinical Trial Site Capabilities
Grant Avenue Capital Recapitalizes CREO
Monroe Biomedical Research Acquired by New Harbor Capital in a First Step to Build-out a Clinical Research Site Platform
SSI Strategy, a Portfolio Company of Amulet Capital Partners, Acquired NDA Group AB to Bolster Regulatory Affairs Consulting Capabilities and Expand Into the EU
QDx Pathology, a Portfolio Company of Hadley Capital, Acquired by LabGenomics to Expand Esoteric Testing Capabilities Globally
Catalyst Clinical Research, a Portfolio Company of QHP Capital, Acquired Genpro Research to Expand Global Footprint and Deepen Service Offerings
Accel Research Sites Network Acquired by Alcanza Clinical Research, a portfolio company of Martis Capital, to Expand its Clinical Trial Site Network and Clinical Trial Execution Capabilities
Versiti Acquired Quantigen to Further Expand Clinical Trial Expertise and Service Offering
Access Medical Labs Allies with Grupo Diagnostico Aries to Expand Diagnostic Lab Capabilities into North America
Benchmark Research Acquired by IQVIA, combined with Avacare to Expand Vaccine and Clinical Trial Site Capabilities
Clinical Site Services and Patient Advertising Guru Acquired by American Clinical Research Services to Add Tech-Enabled Patient Recruitment Capabilities
